US2012149044A1PendingUtilityA1
Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
Individually held — no corporate assignee on recordPriority: May 17, 1993Filed: Feb 24, 2012Published: Jun 14, 2012
Est. expiryMay 17, 2013(expired)· nominal 20-yr term from priority
C07K 2317/76C12N 15/1136A61P 43/00C07K 16/24A61K 2039/505A01K 2267/0337A01K 2267/03C12N 15/113A61K 48/00A01K 2217/05A01K 2217/075C07K 2317/73C07K 16/26C07K 14/72C12N 15/8509C07K 14/575C07K 14/52C12N 15/1138Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.
Claims
exact text as granted — not AI-modified1 . A method of using a diagnostic kit, comprising contacting a sample with:
(a) an antibody or antigen-binding fragment or fusion protein thereof that specifically binds to human macrophage migration inhibitory factor (MIF) protein, wherein the human MIF protein has a molecular weight of approximately 12.5 kDa as determined by SDS PAGE; and (b) a detectable label, whereby the binding of the antibody or antigen-binding fragment or fusion protein to the human MIF protein can be detected.
2 . A method for detecting human macrophage migration inhibitory factor (MIF) protein in a sample, comprising:
(a) contacting the sample with the kit of Claim 1 ; and (b) determining the presence or absence of human MIF protein in the sample, wherein if the human MIF protein is detected, then the human MIF protein is present in the sample, and wherein if the human MIF protein is not detected, then the human MIF protein is not present in the sample.Join the waitlist — get patent alerts
Track US2012149044A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.